Chemotherapy and Radiotherapy for Lung Cancer
Author Information
Author(s): Ardizzoni A, Grossi F, Scolaro T, Giudici S, Foppiano F, Boni L, Tixi L, Cosso M, Mereu C, Ratto G Battista, Vitale V, Rosso R
Primary Institution: Istituto Nazionale per la Ricerca sul Cancro and Centro di Biotecnologie Avanzate
Hypothesis
Can a novel chemoradiation regimen improve outcomes in patients with locally advanced non-small-cell lung cancer?
Conclusion
The study found that the novel chemoradiation regimen is active and feasible with promising long-term survival results.
Supporting Evidence
- Induction chemotherapy consisted of vinblastine and cisplatin followed by concurrent radiotherapy.
- 31% of patients experienced grade III–IV leukopenia during induction chemotherapy.
- 56% of patients had a major response to the treatment.
- The median survival was 12.5 months with a follow-up of 38.4 months.
Takeaway
Doctors tested a new treatment for lung cancer that combines chemotherapy and radiation, and it seems to help patients live longer with fewer side effects.
Methodology
This phase II study involved induction chemotherapy followed by standard radiotherapy and concurrent daily low-dose cisplatin in patients with unresectable stage IIIA/B NSCLC.
Limitations
The study had a small sample size and was limited to a specific patient population.
Participant Demographics
Patients with histologically/cytologically proven unresectable stage IIIA/B NSCLC.
Statistical Information
Confidence Interval
95% CI 38–73%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website